Advertisement

Type 1 Sialidosis Patient With a Novel Deletion Mutation in the NEU1 Gene: Case Report and Literature Review

  • Jong Hyeon Ahn
  • Ah Reum Kim
  • Chung Lee
  • Nayoung K. D. Kim
  • Nam-Soon Kim
  • Woong-Yang Park
  • Minkyeong Kim
  • Jinyoung Youn
  • Jin Whan Cho
  • Ji Sun KimEmail author
Short Report

Abstract

Recent advances in next-generation sequencing technologies have uncovered the genetic backgrounds of various diseases. Type 1 sialidosis (OMIM#256550) is a rare autosomal recessive lysosomal storage disease caused by a mutation in the NEU1 (OMIM * 608272) gene. In this study, we aimed to review the previous reports of type 1 sialidosis and compare those with the first case of type 1 sialidosis in Korea. A 36-year-old woman presented with progressive ataxia, myoclonus, and seizure since the age of 12. Whole-exome sequencing revealed a pathogenic missense variant c.928G > A (p.D310N) and novel c.15_16del (p.P6Qfs*21) of the NEU1 gene as final causal candidate as compound heterozygotes. We reviewed the literature and selected the clinical reports of genetically confirmed type 1 sialidosis patients. A total of 45 patients in 17 reports were identified. Cherry-red spot, myoclonus, ataxia, and seizure were reported in 51.2%, 100.0%, 87.8%, and 73.7% of patients, respectively. Abnormalities of cognitive function, EEG, and brain MRI and visual symptoms were reported in 22.2%, 40.7%, 66.7%, and 70.2% of patients, respectively. Overall, our patient showed similar clinical features to previous type 1 sialidosis patients, but she did not complain of visual symptoms despite having cherry-red spots. We summarize the clinical features of type 1 sialidosis and report the first case of type 1 sialidosis with novel deletion variant in the NEU1 gene in the Korean population. Our study suggests the importance of ophthalmologic examinations in patients with myoclonus, ataxia, and seizure who do not complain of visual symptoms.

Keywords

Sialidosis NEU1 gene Next-generation sequencing Lysosomal storage disease 

Notes

Funding Information

This work was supported by the KRIBB Research Initiative Program and by the Basic Science Research Program of the National Research Foundation of Korea (NRF) funded by the Ministry of Science and ICT (NRF-2014M3C9A2064619). This work was also supported by the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Korean government the Ministry of Science and ICT (NRF-2017R1A2B4005276).

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Bonten E, van der Spoel A, Fornerod M, Grosveld G, d'Azzo A. Characterization of human lysosomal neuraminidase defines the molecular basis of the metabolic storage disorder sialidosis. Genes Dev. 1996;10(24):3156–69.CrossRefGoogle Scholar
  2. 2.
    Pshezhetsky AV, Richard C, Michaud L, Igdoura S, Wang S, Elsliger MA, et al. Cloning, expression and chromosomal mapping of human lysosomal sialidase and characterization of mutations in sialidosis. Nat Genet. 1997;15(3):316–20.  https://doi.org/10.1038/ng0397-316.CrossRefPubMedGoogle Scholar
  3. 3.
    Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405–24.  https://doi.org/10.1038/gim.2015.30.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Naganawa Y, Itoh K, Shimmoto M, Takiguchi K, Doi H, Nishizawa Y, et al. Molecular and structural studies of Japanese patients with sialidosis type 1. J Hum Genet. 2000;45(4):241–9.  https://doi.org/10.1007/s100380070034. CrossRefPubMedGoogle Scholar
  5. 5.
    Bonten EJ, Arts WF, Beck M, Covanis A, Donati MA, Parini R, et al. Novel mutations in lysosomal neuraminidase identify functional domains and determine clinical severity in sialidosis. Hum Mol Genet. 2000;9(18):2715–25.  https://doi.org/10.1093/hmg/9.18.2715.CrossRefPubMedGoogle Scholar
  6. 6.
    Palmeri S, Villanova M, Malandrini A, van Diggelen OP, Huijmans JG, Ceuterick C, et al. Type I sialidosis: a clinical, biochemical and neuroradiological study. Eur Neurol. 2000;43(2):88–94.  https://doi.org/10.1159/000008141.CrossRefPubMedGoogle Scholar
  7. 7.
    Lukong KE. Characterization of the sialidase molecular defects in sialidosis patients suggests the structural organization of the lysosomal multienzyme complex. Hum Mol Genet. 2000;9(7):1075–85.  https://doi.org/10.1093/hmg/9.7.1075.CrossRefPubMedGoogle Scholar
  8. 8.
    Itoh K, Naganawa Y, Matsuzawa F, Aikawa S, Doi H, Sasagasako N, et al. Novel missense mutations in the human lysosomal sialidase gene in sialidosis patients and prediction of structural alterations of mutant enzymes. J Hum Genet. 2002;47(1):29–37.  https://doi.org/10.1007/s10038-002-8652-7. CrossRefPubMedGoogle Scholar
  9. 9.
    Lai SC, Chen RS, Wu Chou YH, Chang HC, Kao LY, Huang YZ, et al. A longitudinal study of Taiwanese sialidosis type 1: an insight into the concept of cherry-red spot myoclonus syndrome. Eur J Neurol. 2009;16(8):912–9.  https://doi.org/10.1111/j.1468-1331.2009.02622.x.CrossRefPubMedGoogle Scholar
  10. 10.
    Ranganath P, Sharma V, Danda S, Nandineni MR, Dalal AB. Novel mutations in the neuraminidase-1 (NEU1) gene in two patients of sialidosis in India. Indian J Med Res. 2012;136(6):1048–50.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Sekijima Y, Nakamura K, Kishida D, Narita A, Adachi K, Ohno K, et al. Clinical and serial MRI findings of a sialidosis type I patient with a novel missense mutation in the NEU1 gene. Intern Med (Tokyo, Japan). 2013;52(1):119–24.CrossRefGoogle Scholar
  12. 12.
    Sobral I, Cachulo Mda L, Figueira J, Silva R. Sialidosis type I: ophthalmological findings. BMJ Case Rep. 2014;2014:bcr2014205871.  https://doi.org/10.1136/bcr-2014-205871. CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Canafoglia L, Robbiano A, Pareyson D, Panzica F, Nanetti L, Giovagnoli AR, et al. Expanding sialidosis spectrum by genome-wide screening: NEU1 mutations in adult-onset myoclonus. Neurology. 2014;82(22):2003–6.  https://doi.org/10.1212/wnl.0000000000000482.CrossRefPubMedGoogle Scholar
  14. 14.
    Schene IF, Kalinina Ayuso V. de Sain-van der Velden M, van Gassen KL, Cuppen I, van Hasselt PM, et al. pitfalls in diagnosing neuraminidase deficiency: psychosomatics and Normal sialic acid excretion. JIMD Rep. 2016;25:9–13.  https://doi.org/10.1007/8904_2015_472. CrossRefPubMedGoogle Scholar
  15. 15.
    Mütze U, Bürger F, Hoffmann J, Tegetmeyer H, Heichel J, Nickel P, et al. Multigene panel next generation sequencing in a patient with cherry red macular spot: identification of two novel mutations in NEU1 gene causing sialidosis type I associated with mild to unspecific biochemical and enzymatic findings. Mol Gen Metab Rep. 2017;10:1–4.  https://doi.org/10.1016/j.ymgmr.2016.11.004. CrossRefGoogle Scholar
  16. 16.
    Gowda VK, Srinivasan VM, Benakappa N, Benakappa A. Sialidosis type 1 with a novel mutation in the Neuraminidase-1 (NEU1) gene. Indian J Pediatr. 2017;84(5):403–4.  https://doi.org/10.1007/s12098-016-2286-9.CrossRefPubMedGoogle Scholar
  17. 17.
    Aravindhan A, Veerapandiyan A, Earley C, Thulasi V, Kresge C, Kornitzer J. Child neurology: type 1 sialidosis due to a novel mutation in NEU1 gene. Neurology. 2018;90(13):622–4.  https://doi.org/10.1212/wnl.0000000000005209.CrossRefPubMedGoogle Scholar
  18. 18.
    Hu SC, Hung KL, Chen HJ, Lee WT. Seizure remission and improvement of neurological function in sialidosis with perampanel therapy. Epilepsy Behav Case Rep. 2018;10:32–4.  https://doi.org/10.1016/j.ebcr.2018.02.005.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Mohammad AN, Bruno KA, Hines S, Atwal PS. Type 1 sialidosis presenting with ataxia, seizures and myoclonus with no visual involvement. Mol Gen Metab Rep. 2018;15:11–4.  https://doi.org/10.1016/j.ymgmr.2017.12.005.CrossRefGoogle Scholar
  20. 20.
    Gultekin M, Bayramov R, Karaca C, Acer N. Sialidosis type I presenting with a novel mutation and advanced neuroimaging features. Neurosciences (Riyadh, Saudi Arabia). 2018;23(1):57–61.  https://doi.org/10.17712/nsj.2018.1.20170328. CrossRefGoogle Scholar
  21. 21.
    Lu CS, Ng SH, Lai SC, Kao LY, Liu L, Lin WY, et al. Cortical damage in the posterior visual pathway in patients with sialidosis type 1. Brain Imaging Behav. 2017;11(1):214–23.  https://doi.org/10.1007/s11682-016-9517-6.CrossRefPubMedGoogle Scholar
  22. 22.
    d'Azzo A, Machado E, Annunziata I. Pathogenesis, emerging therapeutic targets and treatment in Sialidosis. Expert Opin Orphan Drugs. 2015;3(5):491–504.  https://doi.org/10.1517/21678707.2015.1025746.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Kalviainen R. Progressive myoclonus epilepsies. Semin Neurol. 2015;35(3):293–9.  https://doi.org/10.1055/s-0035-1552620.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Jong Hyeon Ahn
    • 1
    • 2
  • Ah Reum Kim
    • 3
  • Chung Lee
    • 3
  • Nayoung K. D. Kim
    • 3
  • Nam-Soon Kim
    • 4
    • 5
  • Woong-Yang Park
    • 3
    • 6
  • Minkyeong Kim
    • 1
    • 2
  • Jinyoung Youn
    • 1
    • 2
  • Jin Whan Cho
    • 1
    • 2
  • Ji Sun Kim
    • 1
    • 2
    Email author
  1. 1.Department of Neurology, Samsung Medical CenterSungkyunkwan University School of MedicineSeoulRepublic of Korea
  2. 2.Neuroscience Center, Samsung Medical CenterSeoulRepublic of Korea
  3. 3.Samsung Medical CenterSamsung Genome InstituteSeoulRepublic of Korea
  4. 4.Research CenterKorea Research Institute of Bioscience and Biotechnology (KRIBB)DaejeonRepublic of Korea
  5. 5.Department of Functional Genomics, KRIBB School of BioscienceKorea University of Science and Technology (UST)DaejeonRepublic of Korea
  6. 6.Department of Molecular Cell BiologySungkyunkwan University School of MedicineSuwonRepublic of Korea

Personalised recommendations